GlassScriptPhysician profile
Leslie Bredes
NPI 1528460169
$5,158.31
in general payments reported to CMS, 2019-2025
34 companies · $899 in 2025
The $899 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $817 · 2022: $1,334 · 2023: $1,059 · 2024: $1,049 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,144.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $805.21 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $436.73 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $418.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.44 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $280.87 | 2021-2025 | Gardasil 9, Capvaxive, Steglatro |
| Lilly USA, LLC | $268.18 | 2021-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $239.48 | 2021-2023 | |
| Exact Sciences Corporation | $173.98 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $103.76 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $93.59 | 2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $90.12 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $85.68 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $84.09 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $80.14 | 2021-2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $63.46 | 2022-2024 | Jynarque |
| Dynavax Technologies Corporation | $55.76 | 2021-2024 | Heplisav-B |
| Sanofi Pasteur INC. | $47.51 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $39.37 | 2021 | |
| Lundbeck LLC | $37.61 | 2022 | |
| Nevro Corp. | $32.05 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.41 | 2024 | Terlivaz |
| Amgen INC. | $31.00 | 2023 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $28.32 | 2025 | |
| Althera Pharmaceuticals LLC | $24.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.86 | 2022 | |
| Amarin Pharma, INC. | $21.74 | 2022 | |
| Philips North America LLC | $21.08 | 2024 | (Ck7) Extended Holter |
| Novartis Pharmaceuticals Corporation | $20.04 | 2021 | |
| Shield Therapeutics INC | $18.15 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.55 | 2023 | Eliquis |
| Abbott Laboratories | $13.35 | 2022 | |
| Phadia US INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Bredes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.